Associated Papers
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Roa P et al.
British Journal of Cancer, 2024
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cocco E et al.
Cancer Discovery, 2021
Select a paper to view details